Dr. Reddy's Laboratories, Incorporated

Dr. Reddy's Research Foundation

Reddy US Therapeutics, Inc.

Javed Iqbal

Ranjan Chakrabarti

Rajagopalan Ramanujam

Saibal Kumar Das

Jagattaran Das

Sitaram Kumar Magadi

Braj Bhushan Lohray

Gurram Ranga Madhavan

Sanjay Trehan

Christopher W Alexander

Manojit Pal

Ish Khanna

Reeba Kannimel Vikramadithyan

Srinivas Oruganti

Ramanujam Rajagopalan

Natesan Selvakumar

Bhuniya Debnath

Baskaran Sundarababu

Selavakumar Natesan

Naga Venkata Srinivasa Rao Mamidi

Selvakumar Natesan

Srinivasa Rao Naga Venkata Mamidi

Vidya Bhushan Lohray

Sivaram Pillarisetti

Ranga Madhavan Gurram

Koteswar Rao Yeleswarapu

Pradip Kumar Sasmal

Vijay Potluri

Shivaramayya Kalchar

Vishweshwar Peddy

Rajesham Boge

Ashok Channaveerappa Bajji

Srividya Ramakrishnan

Jennepalli Sreenu

Santanu Maitra

Parimal Misra

Srinivas Katkam

Babu Ireni

Mohamed Takhi

Srinivas Padakanti

Ram Pillarisetti

Sreenivas Kandepu

Rajeswar Reddy Sagyam

Gurram Ranga Madhaven

Bhaskar Kandagatla

Krishna Vinigari

Sesha Reddy Yarraguntla

Deepika Pathivada

Magadi Sitaram Kumar

Rashmi Talwar

Mamidi Naga Venkata Srinivasa Rao

Gavara Govinda Rajulu

Srinivas Kalleda

Nalivela Kumara Swamy

Deepak Barange

Gayla W Roberts

Lavanya Sagi

Chintakunta Vamsee Krishna

Rajesh Kumar Rapolu

Raghavendar Rao Morthala

Debnath Bhuniya

Kiran Kumar Doniparthi

Dharma Jagannadha Rao Velaga

Debnath Bhunia

Suresh Kumar Ramdoss

Srinivasulu Rangineni

Sudhakar Reddy Baddam

Arjunkumar Tummala

Anitha Naredla

The present application relates to crystalline and amorphous Vilazodone hydrochloride. The present application further relates to amorphous solid dispersions of vilazodone hydrochloride with pharmaceutically acceptable carriers. The present application also relates to a process for the preparation of form I of vilazodone free base.

Crystalline forms of vilazodone hydrochloride and vilazodone free base

The present application provide processes for the preparation of fingolimod and its pharmaceutically acceptable salts, process for the purification of fingolimod hydrochloride and process for the preparation of amorphous fingolimod hydrochloride.

Preparation of fingolimod and its salts

The present application provides novel thiazole derivatives that are useful as activators of Adenosine 5'-Monophosphate-Activated Protein Kinase and pharmaceutical compositions containing such compounds.

Thiazoles derivatives as AMPK activator

In accordance with one aspect, the present invention provides a compound of general formula (I), its stereoisomers thereof and/or its pharmaceutically acceptable salts thereof, which have antibacterial activity; with methods of treating infectious diseases in warm blooded animals employing these new compounds. 

Tetracycline derivatives as antibacterial agents

The present invention is directed to a compounds, methods and compositions for making the compounds and methods of treating a variety of diseases and disease states including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan, comprising the administration of new heterocyclic compounds, particularly substituted pyrimidines. The present invention is directed to novel compounds represented by the general formula: 

Pyrimidine compounds, process for their preparation and compositions containing them

The present invention provides new heterocyclic compounds, particularly substituted pyridines, methods and compositions for making and using these heterocyclic compounds, and methods for treating a variety of diseases and disease states, including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan.

Pyridine compounds, process for their preparation and compositions containing them

The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.

Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them

The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I) their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, to a process for preparing such compounds. More particularly, the present invention relates to novel alkyl carboxylic acids of the general, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, to a process for preparing such compounds. The present invention also relates to processes for the preparation of the compounds of formula (I), novel intermediates, processes for their preparation, their use in the preparation of the above said compounds and their use as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds 

Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them

The present invention relates to novel hypolipidemic, antihyperglycemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel &#x3b2;-aryl-&#x3b1;-oxysubstituted alkylcarboxylic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. 

Monocyclic derivatives of aryl alkanoic acids and their use in medicine: process for their preparation and pharmaceutical compositions containing them

The present invention relates to novel triazole compounds of formula (I), their derivatives, their analogs, their tautomeric forms, their regioisomers, their rotamers, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them. More particularly, the present invention relates to novel triazoles of the general formula (I) their derivatives, their analogs, their tautomeric forms, their regioisomers, their rotamers, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them.

Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them

The present invention relates to novel oxazolidinone compounds of the general formula (I). where R, R, R, Y, Y, Y, and Z are as defined in the description; their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them.

Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them

The present invention relates to novel oxazolidinone compounds of formula (I), their stereoisomers, their salts and pharmaceutical compositions containing them.  The present invention also relates to a process for the preparation of the above said novel compounds, their stereoisomers, their salts and pharmaceutical compositions.

The present invention relates to novel oxazolidinone compounds of the general formula (I)where R, R, R, Y, Y, Y, and Z are as defined in the description; their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutical acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them.

The present invention relates to novel triazole compounds of formula (I), their derivatives, their analogs, their tautomeric forms, their regioisomers, their rotammers, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them. More particularly, the present invention relates to novel triazoles of the general formula (I)their derivatives, their analogs, their tautomeric forms, their regioisomers, their rotamers, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them.

Growing community of inventors

Hyderabad Telangana, India

Javed Iqbal